Abstract
The primary filtration of blood occurs in the glomerulus in the kidney. Destruction of any of the layers of the glomerular filtration barrier might result in proteinuric disease. The glomerular endothelial cells and especially its covering layer, the glycocalyx, play a pivotal role in development of albuminuria. One of the main sulfated glycosaminoglycans in the glomerular endothelial glycocalyx is heparan sulfate. The endoglycosidase heparanase degrades heparan sulfate, thereby affecting glomerular barrier function, immune reactivity and inflammation. Increased expression of glomerular heparanase correlates with loss of glomerular heparan sulfate in many glomerular diseases. Most importantly, heparanase knockout in mice prevented the development of albuminuria after induction of experimental diabetic nephropathy and experimental glomerulonephritis. Therefore, heparanase could serve as a pharmacological target for glomerular diseases. Several factors that regulate heparanase expression and activity have been identified and compounds aiming to inhibit heparanase activity are currently explored.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Scott, R. P., & Quaggin, S. E. (2015, April). The cell biology of renal filtration. The Journal of Cell Biology, 209(2), 199–210.
Miner, J. H. (2012, May). The glomerular basement membrane. Experimental Cell Research, 318(9), 973–978.
Haraldsson, B., Nystrom, J., & Deen, W. M. (2008, April). Properties of the glomerular barrier and mechanisms of proteinuria. Physiological Reviews, 88(2), 451–487.
Shute, J. (2012). Glycosaminoglycan and chemokine/growth factor interactions. Handbook of experimental pharmacology, 207, 307–324.
Maezawa, Y., Takemoto, M., & Yokote, K. (2015, January). Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes. Journal of diabetes investigation, 6(1), 3–15.
Schött, U., Solomon, C., Fries, D., & Bentzer, P. (2016, April). The endothelial glycocalyx and its disruption, protection and regeneration: A narrative review. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 24, 48.
Goldberg, R., Rubinstein, A. M., Gil, N., Hermano, E., Li, J. P., van der Vlag, J., et al. (2014, December). Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy. Diabetes, 63(12), 4302–4313.
Friden, V., Oveland, E., Tenstad, O., Ebefors, K., Nystrom, J., Nilsson, U. A., et al. (2011, June). The glomerular endothelial cell coat is essential for glomerular filtration. Kidney International, 79(12), 1322–1330.
Reiser, J., & Altintas, M. M. (2016, January). Podocytes. F1000Research, 5: F1000 Faculty Rev-114.
Ichimura, K., Kurihara, H., & Sakai, T. (2003, December). Actin filament organization of foot processes in rat podocytes. The Journal of Histochemistry and Cytochemistry, 51(12), 1589–1600.
Kriz, W., Hackenthal, E., Nobiling, R., Sakai, T., Elger, M., & Hahnel, B. (1994, February). A role for podocytes to counteract capillary wall distension. Kidney International, 45(2), 369–376.
Garsen, M., Lenoir, O., Rops, A. L., Dijkman, H. B., Willemsen, B., van Kuppevelt, T. H., et al. (2016, December). Endothelin-1 induces proteinuria by Heparanase-mediated disruption of the glomerular Glycocalyx. Journal of the American Society of Nephrology, 27(12), 3545–3551.
Haraldsson, B., & Nystrom, J. (2012, May). The glomerular endothelium: New insights on function and structure. Current Opinion in Nephrology and Hypertension, 21(3), 258–263.
Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchalia, T., & Risau, W. (1998, February). Vascular endothelial growth factor induces endothelial fenestrations in vitro. The Journal of Cell Biology, 140(4), 947–959.
van den Hoven, M. J., Rops, A. L., Vlodavsky, I., Levidiotis, V., Berden, J. H., & van der Vlag, J. (2007, September). Heparanase in glomerular diseases. Kidney International, 72(5), 543–548.
Goldberg, S., Harvey, S. J., Cunningham, J., Tryggvason, K., & Miner, J. H. (2009, July). Glomerular filtration is normal in the absence of both agrin and perlecan-heparan sulfate from the glomerular basement membrane. Nephrology, Dialysis, Transplantation, 24(7), 2044–2051.
Harvey, S. J., Jarad, G., Cunningham, J., Rops, A. L., van der Vlag, J., Berden, J. H., et al. (2007, July). Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. The American Journal of Pathology, 171(1), 139–152.
Chen, S., Wassenhove-McCarthy, D. J., Yamaguchi, Y., Holzman, L. B., van Kuppevelt, T. H., Jenniskens, G. J., et al. (2008, August). Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria. Kidney International, 74(3), 289–299.
van den Hoven, M. J., Wijnhoven, T. J., Li, J. P., Zcharia, E., Dijkman, H. B., Wismans, R. G., et al. (2008, February). Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney International, 73(3), 278–287.
Bame, K. J. (2001, June). Heparanases: Endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology, 11(6), 91r–98r.
Wilson, J. C., Laloo, A. E., Singh, S., & Ferro, V. (2014, January). 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase. Biochemical and Biophysical Research Communications, 443(1), 185–188.
Wu, L., Viola, C. M., Brzozowski, A. M., & Davies, G. J. (2015, December). Structural characterization of human heparanase reveals insights into substrate recognition. Nature Structural & Molecular Biology, 22(12), 1016–1022.
Rabelink, T. J., van den Berg, B. M., Garsen, M., Wang, G., Elkin, M., & van der Vlag, J. (2017, April). Heparanase: Roles in cell survival, extracellular matrix remodelling and the development of kidney disease. Nature Reviews Nephrology, 13(4), 201–212.
Abboud-Jarrous, G., Atzmon, R., Peretz, T., Palermo, C., Gadea, B. B., Joyce, J. A., et al. (2008, June). Cathepsin L is responsible for processing and activation of Proheparanase through multiple cleavages of a linker segment. The Journal of Biological Chemistry, 283(26), 18167–18176.
Buczek-Thomas, J. A., Hsia, E., Rich, C. B., Foster, J. A., & Nugent, M. A. (2008, September). Inhibition of histone Acetyltransferase by Glycosaminoglycans. Journal of Cellular Biochemistry, 105(1), 108–120.
Stewart, M. D., & Sanderson, R. D. (2014, April). Heparan sulfate in the nucleus and its control of cellular functions. Matrix Biology, 35, 56–59.
Wang, F., Wang, Y., Zhang, D., Puthanveetil, P., Johnson, J. D., & Rodrigues, B. (2012, February). Fatty acid-induced nuclear translocation of heparanase uncouples glucose metabolism in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(2), 406–414.
Roy, M., & Marchetti, D. (2009). Cell surface Heparan Sulfate released by Heparanase promotes melanoma cell migration and angiogenesis. Journal of Cellular Biochemistry, 106(2), 200–209.
Sasaki, N., Higashi, N., Taka, T., Nakajima, M., Irimura, T. (2004, March). Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate. Journal of Immunology, 172(6), 3830–3835.
Ziolkowski, A. F., Popp, S. K., Freeman, C., Parish, C. R., Simeonovic, C. J. (2012, January). Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes. The Journal of Clinical Investigation, 122(1), 132–141.
Sanderson, R. D., Elkin, M., Rapraeger, A. C., Ilan, N., & Vlodavsky, I. (2017, September). Heparanase regulation of cancer, autophagy and inflammation: New mechanisms and targets for therapy. The FEBS Journal, 284(1), 42–55.
Goldberg, R., Meirovitz, A., Hirshoren, N., Bulvik, R., Binder, A., Rubinstein, A. M., et al. (2013, June). Versatile role of heparanase in inflammation. Matrix Biology, 32(5), 234–240.
Garsen, M., Rops, A. L., Rabelink, T. J., Berden, J. H., & van der Vlag, J. (2014, January). The role of heparanase and the endothelial glycocalyx in the development of proteinuria. Nephrology, Dialysis, Transplantation, 29(1), 49–55.
Levidiotis, V., Kanellis, J., Ierino, F. L., & Power, D. A. (2001, October). Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney International, 60(4), 1287–1296.
Levidiotis, V., Freeman, C., Tikellis, C., Cooper, M. E., & Power, D. A. (2004, January). Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. Journal of the American Society of Nephrology, 15(1), 68–78.
Levidiotis, V., Freeman, C., Punler, M., Martinello, P., Creese, B., Ferro, V., et al. (2004, November). A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. Journal of the American Society of Nephrology, 15(11), 2882–2892.
Simeonovic, C. J., Ziolkowski, A. F., Wu, Z., Choong, F. J., Freeman, C., & Parish, C. R. (2013, December). Heparanase and autoimmune diabetes. Frontiers in Immunology, 4, 471.
Gil, N., Goldberg, R., Neuman, T., Garsen, M., Zcharia, E., Rubinstein, A. M., et al. (2012, January). Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes, 61(1), 208–216.
van den Hoven, M. J., Rops, A. L., Bakker, M. A., Aten, J., Rutjes, N., Roestenberg, P., et al. (2006, December). Increased expression of heparanase in overt diabetic nephropathy. Kidney International, 70(12), 2100–2108.
Garsen, M., Benner, M., Dijkman, H. B., van Kuppevelt, T. H., Li, J. P., Rabelink, T. J., et al. (2016, April). Heparanase is essential for the development of acute experimental glomerulonephritis. The American Journal of Pathology, 186(4), 805–815.
Ilan, N., Shteingauz, A., & Vlodavsky, I. (2015). Function from within: Autophagy induction by HPSE/heparanase—New possibilities for intervention. Autophagy, 11(12), 2387–2389.
Sever, S., Altintas, M. M., Nankoe, S. R., Moller, C. C., Ko, D., Wei, C., et al. (2007, August). Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. The Journal of Clinical Investigation, 117(8), 2095–2104.
Faul, C., Donnelly, M., Merscher-Gomez, S., Chang, Y. H., Franz, S., Delfgaauw, J., et al. (2008, September). The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine a. Nature Medicine, 14(9), 931–938.
Yaddanapudi, S., Altintas, M. M., Kistler, A. D., Fernandez, I., Moller, C. C., Wei, C., et al. (2011, October). CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. The Journal of Clinical Investigation, 121(10), 3965–3980.
Lehtonen, S., Zhao, F., & Lehtonen, E. (2002, October). CD2-associated protein directly interacts with the actin cytoskeleton. American Journal of Physiology Renal Physiology, 283(4), F734–F743.
Reiser, J., Adair, B., & Reinheckel, T. (2010, October). Specialized roles for cysteine cathepsins in health and disease. The Journal of Clinical Investigation, 120(10), 3421–3431.
Kim, J. M., Wu, H., Green, G., Winkler, C. A., Kopp, J. B., Miner, J. H., et al. (2003, May). CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science, 300(5623), 1298–1300.
Huber, T. B., Kwoh, C., Wu, H., Asanuma, K., Godel, M., Hartleben, B., et al. (2006, May). Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin. The Journal of Clinical Investigation, 116(5), 1337–1345.
Mundel, P., & Reiser, J. (2010, April). Proteinuria: An enzymatic disease of the podocyte? Kidney International, 77(7), 571–580.
Garsen, M., Rops, A. L., Dijkman, H., Willemsen, B., van Kuppevelt, T. H., Russel, F. G., et al. (2016, November). Cathepsin L is crucial for the development of early experimental diabetic nephropathy. Kidney International, 90(5), 1012–1022.
Baricos, W. H., Cortez, S. L., Le, Q. C., Wu, L. T., Shaw, E., Hanada, K., et al. (1991, August). Evidence suggesting a role for cathepsin L in an experimental model of glomerulonephritis. Archives of Biochemistry and Biophysics, 288(2), 468–472.
Lehrke, I., Waldherr, R., Ritz, E., & Wagner, J. (2001, November). Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. Journal of the American Society of Nephrology, 12(11), 2321–2329.
Karet, F. E., Kuc, R. E., & Davenport, A. P. (1993, July). Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney International, 44(1), 36–42.
Wendel, M., Knels, L., Kummer, W., & Koch, T. (2006, November). Distribution of endothelin receptor subtypes ETA and ETB in the rat kidney. The Journal of Histochemistry and Cytochemistry, 54(11), 1193–1203.
Barton, M., & Yanagisawa, M. (2008, August). Endothelin: 20 years from discovery to therapy. Canadian Journal of Physiology and Pharmacology, 86(8), 485–498.
Clozel, M., & Salloukh, H. (2005). Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Annals of Medicine, 37(1), 2–12.
Shi-Wen, X., Denton, C. P., Dashwood, M. R., Holmes, A. M., Bou-Gharios, G., Pearson, J. D., et al. (2001, March). Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. The Journal of Investigative Dermatology, 116(3), 417–425.
Neuhofer, W., & Pittrow, D. (2006, September). Role of endothelin and endothelin receptor antagonists in renal disease. European Journal of Clinical Investigation, 36(Suppl 3), 78–88.
Fukui, M., Nakamura, T., Ebihara, I., Osada, S., Tomino, Y., Masaki, T., et al. (1993, August). Gene expression for endothelins and their receptors in glomeruli of diabetic rats. The Journal of Laboratory and Clinical Medicine, 122(2), 149–156.
Fligny, C., Barton, M., & Tharaux, P. L. (2011). Endothelin and podocyte injury in chronic kidney disease. Contributions to Nephrology, 172, 120–138.
Yoshimura, A., Iwasaki, S., Inui, K., Ideura, T., Koshikawa, S., Yanagisawa, M., et al. (1995, October). Endothelin-1 and endothelin B type receptor are induced in mesangial proliferative nephritis in the rat. Kidney International, 48(4), 1290–1297.
Barton, M. (2008, September). Reversal of proteinuric renal disease and the emerging role of endothelin. Nature Clinical Practice Nephrology, 4(9), 490–501.
Mann, J. F., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., et al. (2010, March). Avosentan for overt diabetic nephropathy. Journal of the American Society of Nephrology, 21(3), 527–535.
Schievink, B., de Zeeuw, D., Smink, P. A., Andress, D., Brennan, J. J., Coll, B., et al. (2016, May). Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 23(7), 758–768.
Kohan, D. E., & Barton, M. (2014, November). Endothelin and endothelin antagonists in chronic kidney disease. Kidney International, 86(5), 896–904.
Ortmann, J., Amann, K., Brandes, R. P., Kretzler, M., Munter, K., Parekh, N., et al. (2004, December). Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension, 44(6), 974–981.
Gomez-Garre, D., Largo, R., Liu, X. H., Gutierrez, S., Lopez-Armada, M. J., Palacios, I., et al. (1996, September). An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney International, 50(3), 962–972.
Tousoulis, D., Kampoli, A. M., Tentolouris, C., Papageorgiou, N., & Stefanadis, C. (2012, January). The role of nitric oxide on endothelial function. Current Vascular Pharmacology, 10(1), 4–18.
Davignon, J., & Ganz, P. (2004, June). Role of endothelial dysfunction in atherosclerosis. Circulation, 109(23 Suppl 1), Iii27–Iii32.
Nakayama, T., Sato, W., Kosugi, T., Zhang, L., Campbell-Thompson, M., Yoshimura, A., et al. (2009, February). Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse. American Journal of Physiology Renal Physiology, 296(2), F317–F327.
Sun, Y. B., Qu, X., Zhang, X., Caruana, G., Bertram, J. F., & Li, J. (2013). Glomerular endothelial cell injury and damage precedes that of podocytes in adriamycin-induced nephropathy. PLoS One, 8(1), e55027.
Heeringa, P., van Goor, H., Itoh-Lindstrom, Y., Maeda, N., Falk, R. J., Assmann, K. J., et al. (2000, March). Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis. The American Journal of Pathology., 156(3), 879–888.
Zhao, H. J., Wang, S., Cheng, H., Zhang, M. Z., Takahashi, T., Fogo, A. B., et al. (2006, October). Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. Journal of the American Society of Nephrology, 17(10), 2664–2669.
Nakagawa, T., Sato, W., Glushakova, O., Heinig, M., Clarke, T., Campbell-Thompson, M., et al. (2007, February). Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. Journal of the American Society of Nephrology, 18(2), 539–550.
Kanetsuna, Y., Takahashi, K., Nagata, M., Gannon, M. A., Breyer, M. D., Harris, R. C., et al. (2007, May). Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. The American Journal of Pathology, 170(5), 1473–1484.
Savard, S., Lavoie, P., Villeneuve, C., Agharazii, M., Lebel, M., & Lariviere, R. (2012, June). eNOS gene delivery prevents hypertension and reduces renal failure and injury in rats with reduced renal mass. Nephrology, Dialysis, Transplantation, 27(6), 2182–2190.
Garsen, M., Rops, A. L., Li, J., van Beneden, K., van den Branden, C., Berden, J. H., et al. (2016). Endothelial nitric oxide synthase prevents Heparanase induction and the development of proteinuria. PLoS One, 11(8), e0160894.
Mawer, E. B., Taylor, C. M., Backhouse, J., Lumb, G. A., & Stanbury, S. W. (1973, March). Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet, 1(7804), 626–628.
Garsen, M., Sonneveld, R., Rops, A. L., Huntink, S., van Kuppevelt, T. H., Rabelink, T. J., et al. (2015, December). Vitamin D attenuates proteinuria by inhibition of heparanase expression in the podocyte. The Journal of Pathology, 237(4), 472–481.
Toyoda, M., Najafian, B., Kim, Y., Caramori, M. L., & Mauer, M. (2007, August). Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes, 56(8), 2155–2160.
Weil, E. J., Lemley, K. V., Mason, C. C., Yee, B., Jones, L. I., Blouch, K., et al. (2012, June). Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney International, 82(9), 1010–1017.
Katz, A., Van-Dijk, D. J., Aingorn, H., Erman, A., Davies, M., Darmon, D., et al. (2002, November). Involvement of human heparanase in the pathogenesis of diabetic nephropathy. The Israel Medical Association Journal, 4(11), 996–1002.
Singh, A., Friden, V., Dasgupta, I., Foster, R. R., Welsh, G. I., Tooke, J. E., et al. (2011, January). High glucose causes dysfunction of the human glomerular endothelial glycocalyx. American Journal of Physiology Renal Physiology, 300(1), F40–F48.
Singh, A., Ramnath, R. D., Foster, R. R., Wylie, E. C., Friden, V., Dasgupta, I., et al. (2013). Reactive oxygen species modulate the barrier function of the human glomerular endothelial glycocalyx. PLoS One, 8(2), e55852.
van den Hoven, M. J., Waanders, F., Rops, A. L., Kramer, A. B., van Goor, H., Berden, J. H., et al. (2009, September). Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrology, Dialysis, Transplantation, 24(9), 2637–2645.
Rops, A. L., van den Hoven, M. J., Veldman, B. A., Salemink, S., Vervoort, G., Elving, L. D., et al. (2012, July). Urinary heparanase activity in patients with type 1 and type 2 diabetes. Nephrology, Dialysis, Transplantation, 27(7), 2853–2861.
Duran-Salgado, M. B., & Rubio-Guerra, A. F. (2014, June). Diabetic nephropathy and inflammation. World Journal of Diabetes, 5(3), 393–398.
Lim, A. K. H., & Tesch, G. H. (2012). Inflammation in diabetic nephropathy. Mediators of Inflammation, 2012, 146154.
Navarro-Gonzalez, J. F., Mora-Fernandez, C., Muros de Fuentes, M., & Garcia-Perez, J. (2011, June). Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nature Reviews Nephrology, 7(6), 327–340.
You, H., Gao, T., Cooper, T. K., Brian Reeves, W., & Awad, A. S. (2013, December). Macrophages directly mediate diabetic renal injury. American Journal of Physiology Renal Physiology, 305(12), F1719–F1727.
Tesch, G. H. (2010, May). Macrophages and diabetic nephropathy. Seminars in Nephrology, 30(3), 290–301.
Shanmugam, N., Reddy, M. A., Guha, M., & Natarajan, R. (2003, May). High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes, 52(5), 1256–1264.
Cha, J. J., Hyun, Y. Y., Lee, M. H., Kim, J. E., Nam, D. H., Song, H. K., et al. (2013, June). Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology, 154(6), 2144–2155.
Jin, X., Yao, T., Ze, Z., Zhu, J., Zhang, S., Hu, W., et al. (2015). Advanced Glycation end products enhance macrophages polarization into M1 phenotype through activating RAGE/NF-κB pathway. BioMed Research International, 2015, 732450.
Navarro-Gonzalez, J. F., Jarque, A., Muros, M., Mora, C., & Garcia, J. (2009, April). Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine & Growth Factor Reviews, 20(2), 165–173.
Chow, F. Y., Nikolic-Paterson, D. J., Atkins, R. C., & Tesch, G. H. (2004, December). Macrophages in streptozotocin-induced diabetic nephropathy: Potential role in renal fibrosis. Nephrology, Dialysis, Transplantation, 19(12), 2987–2996.
Tashiro, K., Koyanagi, I., Saitoh, A., Shimizu, A., Shike, T., Ishiguro, C., et al. (2002). Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. Journal of Clinical Laboratory Analysis, 16(1), 1–4.
Boels, M. G. S., Koudijs, A., Avramut, M. C., Sol, W., Wang, G., van Oeveren-Rietdijk, A. M., et al. (2017, November). Systemic monocyte chemotactic Protein-1 inhibition modifies renal macrophages and restores glomerular endothelial Glycocalyx and barrier function in diabetic nephropathy. The American Journal of Pathology, 187(11), 2430–2440.
Lerner, I., Hermano, E., Zcharia, E., Rodkin, D., Bulvik, R., Doviner, V., et al. (2011, May). Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. The Journal of Clinical Investigation, 121(5), 1709–1721.
Goodall, K. J., Poon, I. K., Phipps, S., & Hulett, M. D. (2014). Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. PLoS One, 9(10), e109596.
Devaraj, S., Tobias, P., Kasinath, B. S., Ramsamooj, R., Afify, A., & Jialal, I. (2011, August). Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(8), 1796–1804.
Blich, M., Golan, A., Arvatz, G., Sebbag, A., Shafat, I., Sabo, E., et al. (2013, February). Macrophages activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(2), e56–e65.
Gordts, P., Foley, E. M., Lawrence, R., Sinha, R., Lameda-Diaz, C., Deng, L., et al. (2014, November). Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. Cell Metabolism, 20(5), 813–826.
Gordts, P. L. S. M., & Esko, J. D. (2015, March). Heparan sulfate proteoglycans fine-tune macrophage inflammation via IFN-β. Cytokine, 72(1), 118–119.
Goldberg, R., Sonnenblick, A., Hermano, E., Hamburger, T., Meirovitz, A., Peretz, T., et al. (2017, March). Heparanase augments insulin receptor signaling in breast carcinoma. Oncotarget, 8(12), 19403–19412.
Ritchie, J. P., Ramani, V. C., Ren, Y., Naggi, A., Torri, G., Casu, B., et al. (2011, March). SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clinical Cancer Research, 17(6), 1382–1393.
Kuhnast, B., El Hadri, A., Boisgard, R., Hinnen, F., Richard, S., Caravano, A., et al. (2016, February). Synthesis, radiolabeling with fluorine-18 and preliminary in vivo evaluation of a heparan sulphate mimetic as potent angiogenesis and heparanase inhibitor for cancer applications. Organic & Biomolecular Chemistry, 14(6), 1915–1920.
Xu, D., & Esko, J. D. (2014). Demystifying heparan sulfate-protein interactions. Annual Review of Biochemistry, 83, 129–157.
Blich, M., Golan, A., Arvatz, G., Sebbag, A., Shafat, I., Sabo, E., et al. (2013, February). Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(2), e56–e65.
Nadanaka, S., Purunomo, E., Takeda, N., Tamura, J., & Kitagawa, H. (2014, May). Heparan sulfate containing unsubstituted glucosamine residues: Biosynthesis and heparanase-inhibitory activity. The Journal of Biological Chemistry, 289(22), 15231–15243.
Niu, T. T., Zhang, D. S., Chen, H. M., & Yan, X. J. (2015, July). Modulation of the binding of basic fibroblast growth factor and heparanase activity by purified lambda-carrageenan oligosaccharides. Carbohydrate Polymers, 125, 76–84.
Poplawska, A., Szelachowska, M., Topolska, J., Wysocka-Solowie, B., & Kinalska, I. (1997, November). Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Research and Clinical Practice, 38(2), 109–114.
Weissmann, M., Arvatz, G., Horowitz, N., Feld, S., Naroditsky, I., Zhang, Y., et al. (2016, January). Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 113(3), 704–709.
Zetser, A., Levy-Adam, F., Kaplan, V., Gingis-Velitski, S., Bashenko, Y., Schubert, S., et al. (2004, June). Processing and activation of latent heparanase occurs in lysosomes. Journal of Cell Science, 117(Pt 11), 2249–2258.
de Zeeuw, D., Bekker, P., Henkel, E., Hasslacher, C., Gouni-Berthold, I., Mehling, H., et al. (2015, September). The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: A randomised trial. The Lancet Diabetes & Endocrinology, 3(9), 687–696.
Menne, J., Eulberg, D., Beyer, D., Baumann, M., Saudek, F., Valkusz, Z., et al. (2017, February). C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrology, Dialysis, Transplantation, 32(2), 307–315.
Baricos, W. H., O’Connor, S. E., Cortez, S. L., Wu, L. T., & Shah, S. V. (1988, September). The cysteine proteinase inhibitor, E-64, reduces proteinuria in an experimental model of glomerulonephritis. Biochemical and Biophysical Research Communications, 155(3), 1318–1323.
Levy-Adam, F., Feld, S., Cohen-Kaplan, V., Shteingauz, A., Gross, M., Arvatz, G., et al. (2010, September). Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. The Journal of Biological Chemistry, 285(36), 28010–28019.
Guo, C., Kaneko, S., Sun, Y., Huang, Y., Vlodavsky, I., Li, X., et al. (2015, April). A mouse model of urofacial syndrome with dysfunctional urination. Human Molecular Genetics, 24(7), 1991–1999.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
van der Vlag, J., Buijsers, B. (2020). Heparanase in Kidney Disease. In: Vlodavsky, I., Sanderson, R., Ilan, N. (eds) Heparanase. Advances in Experimental Medicine and Biology, vol 1221. Springer, Cham. https://doi.org/10.1007/978-3-030-34521-1_26
Download citation
DOI: https://doi.org/10.1007/978-3-030-34521-1_26
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-34520-4
Online ISBN: 978-3-030-34521-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)